{"id":952764,"date":"2026-04-20T07:08:34","date_gmt":"2026-04-20T11:08:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/"},"modified":"2026-04-20T07:08:34","modified_gmt":"2026-04-20T11:08:34","slug":"caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/","title":{"rendered":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing"},"content":{"rendered":"

<\/p>\n

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing<\/b><\/p>\n

AlloSeq Nano delivers rapid, high\u2011resolution HLA and ABO genotyping in a single assay through a streamlined, long\u2011read workflow designed for transplant and donor typing laboratories.<\/i><\/p>\n

BRISBANE, Calif.–(BUSINESS WIRE<\/a>)–
\nCareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore\u2011based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026.<\/p>\n

\nAlloSeq Nano is an innovation developed by CareDx to deliver high\u2011resolution HLA genotyping in under three hours with streamlined long\u2011read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution.<\/p>\n

\nIn early access testing, Alloseq Nano\u2019s single-step amplification and prep workflow required approximately 45 minutes of hands\u2011on time to assay eleven HLA loci plus ABO in a single test. The assay\u2019s elegant probe redundancy helps minimize allele dropout, while long-read sequencing reduces phasing ambiguities, enhancing overall performance and accuracy.<\/p>\n

\nAlloSeq Nano expands CareDx\u2019s pre\u2011transplant Lab Products portfolio, alongside AlloSeq Tx and QTYPE\u00ae<\/sup>, to support a broader range of laboratory throughput requirements and use cases.<\/p>\n

\nTo introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23, from 13:00\u201314:00 BST, at the Edinburgh Congress Centre, Sidlaw Auditorium. The symposium will feature scientific and educational discussions related to AlloSeq Nano and CareDx\u2019s transplant diagnostics portfolio.<\/p>\n

\nCareDx will also present multiple abstracts at EFI 2026 reflecting scientific engagement across laboratory, clinical, and technical dimensions of transplant diagnostics. Accepted abstracts include presentations featuring AlloSeq cfDNA in kidney and lung transplant settings, as well as a presentation featuring QTYPE\u00ae,<\/sup> highlighting rapid ABO genotyping in combination with HLA typing.<\/p>\n

Lab Products Business Update<\/b><\/p>\n

\nCareDx announced on April 15, 2026 that it entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific, which is expected to close by the end of the third quarter of 2026. CareDx\u2019s Lab Products business consists of IVD (in vitro diagnostic) PCR kits for rapid deceased donor HLA (human leukocyte antigen) typing, IVD NGS-based (next-generation sequencing) kits for transplant recipient HLA typing globally, including AlloSeq Nano; and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.<\/p>\n

About CareDx<\/b><\/p>\n

\nCareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company\u2019s integrated solutions include non\u2011invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics\u2011based information for transplant patients. For more information, please visit www.caredx.com<\/a>.<\/p>\n

Forward Looking Statements<\/b><\/p>\n

\nThis press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with AlloSeq Nano. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSeq Nano, general economic and market factors, and other risks discussed in CareDx\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx\u2019s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx\u2019s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\nAlloSeq Nano, AlloSeq cfDNA, and QTYPE are available as CE-IVD and Research Use Only (RUO). RUO products are not to be used for diagnostic procedures. For local regulatory status, please contact CareDx. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. \u00a9 2026 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its affiliates. All rights reserved.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260420549411\/en\/<\/a><\/span><\/p>\n

CareDx, Inc.
\n<\/b>
Media
\n
Natasha Moshirian Wagner
\n
nwagner@CareDx.com
\n<\/b><\/a>
<\/b>
Investor Relations
\n
Caroline Corner
\n
investor@CareDx.com<\/b><\/a><\/p>\n

KEYWORDS:<\/b> California Europe United States United Kingdom North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Surgery Medical Devices Genetics Health Technology Biotechnology Health Pharmaceutical Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing AlloSeq Nano delivers rapid, high\u2011resolution HLA and ABO genotyping in a single assay through a streamlined, long\u2011read workflow designed for transplant and donor typing laboratories. BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore\u2011based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high\u2011resolution HLA genotyping in under three hours with streamlined long\u2011read library prep … <\/p>\n

Continue reading “CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-952764","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing AlloSeq Nano delivers rapid, high\u2011resolution HLA and ABO genotyping in a single assay through a streamlined, long\u2011read workflow designed for transplant and donor typing laboratories. BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore\u2011based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high\u2011resolution HLA genotyping in under three hours with streamlined long\u2011read library prep … Continue reading "CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T11:08:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing\",\"datePublished\":\"2026-04-20T11:08:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/\"},\"wordCount\":821,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/\",\"name\":\"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-20T11:08:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/","og_locale":"en_US","og_type":"article","og_title":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk","og_description":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing AlloSeq Nano delivers rapid, high\u2011resolution HLA and ABO genotyping in a single assay through a streamlined, long\u2011read workflow designed for transplant and donor typing laboratories. BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) \u2014 The Transplant Company\u2122, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high\u2011value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore\u2011based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high\u2011resolution HLA genotyping in under three hours with streamlined long\u2011read library prep … Continue reading \"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-20T11:08:34+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing","datePublished":"2026-04-20T11:08:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/"},"wordCount":821,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/","name":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-20T11:08:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260420549411r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=952764"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/952764\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=952764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=952764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=952764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}